Although melanoma remains one of the deadliest cancers, accounting for approximately 59,000 deaths worldwide [6], IO improved 5-year OS rates in stage IV melanoma from 15% to 52% with combination anti-PDL-1 and anti-CTLA-4 therapy [3,4,7,8,9]. This evidence concerns the gene CTLA4 and melanoma.